Paradigm Biopharmaceuticals Ltd. · ASX:PAR
Paradigm Biopharmaceuticals — Shareholder Meeting (January 2022)
20 slides from Paradigm Biopharmaceuticals's shareholder meeting presentation, Jan 25, 2022
Slide 1: 2021 Annual General Meeting
ASX RELEASE 25th January 2022 2021 Annual General Meeting For personal use only Paradigm Biopharmaceuticals Ltd (ASX: PAR) (Paradigm or the Company), a clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with unmet clinical needs, is pleased to pro
Slide 2: 2021 AGM Chairman's Address
ASX RELEASE 25th January 2022 2021 AGM Chairman’s Address For personal use only Dear Shareholders, Good morning and I welcome you to this Annual General Meeting of Paradigm Biopharmaceuticals Ltd. I am Paul Rennie Non-Executive Chairman. Today’s meeting is being held online via the Computershare Mee
Slide 3: Chairman's Address (continued)
The significance of this study is also the commercial potential of Zilosul In the amount that the market is prepared to pay for Zilosul. In addition to the progress being made in the clinical development program for osteoarthritis, development of PPS for MPS (where Paradigm has received orphan statu
Slide 4: Further information and contact
To learn more please visit: www.paradigmbiopharma.com Approved for release by the Paradigm Board of Directors FOR FURTHER INFORMATION PLEASE CONTACT: Simon White For personal use only Director of Investor Relations Tel: +61 404 216 467 Paradigm Biopharmaceuticals Ltd ABN: 94 169 346 963 Level 15, 50
Slide 5: Annual General Meeting
For personal use only Annual General Meeting
Slide 6: Disclaimer
For personal use only Paradigm Biopharma 25/01/22 2 Disclaimer This document, together with any information communicated by Paradigm Biopharmaceuticals Ltd ASX:PAR (known as “Paradigm”, “Paradigm Biopharma” or “the Company”), in any presentation or discussion relating to this document (collectively,
Slide 7: Welcome
Paradigm Biopharma 25/01/22 3 Paul For personal use only Rennie, Chairman Welcome
Slide 8: CEO & Business Update
Paradigm Biopharma 25/01/22 4 Dr. Donna For personal use only Skerrett, CMO & Interim CEO CEO & Business Update
Slide 9: Paradigm Biopharmaceuticals Limited (PAR)
For personal use only Paradigm Biopharma 02/12/21 25/01/22 55 Paradigm Biopharmaceuticals Limited (PAR) Paradigm’s is a global biopharmaceutical company driven to improve patients’ lives through repurposing Vision existing drugs and pioneering new solutions for unmet medical needs.
Slide 10: Objectives FY 2021 - Repurpose Pentosan Polysulfate Sodium
Paradigm Biopharma 25/01/22 6 Objectives FY 2021 - Repurpose Pentosan Polysulfate Sodium For personal use only 1. Conduct research and pivotal studies to gather data for successful harmonized global registration/reimbursement and commercialisation-open IND and initiate global phase 3 program 2. Stre
Slide 11: Lead Program Osteoarthritis
Paradigm Biopharma 02/12/21 25/01/22 77 1. Lead Program Osteoarthritis For personal use only De-risked phase 3 asset in blockbuster indication with large unmet medical need Clear Harmonised Pathway • Obtained regulatory feedback (FDA, TGA, EMA) for a harmonised clinical protocol to achieve simultane
Slide 12: Exclusive Supply & Manufacture
Paradigm Biopharma 02/12/21 25/01/22 88 2. Exclusive Supply & Manufacture For personal use only Supply chain ready to partner bene Commercial pharma Chem Partner • Extension of exclusive supply agreement with bene pharmaChem, 25 years from the date of marketing approval. • Expansion of indications c
Slide 13: Pricing and Reimbursement
Paradigm Biopharma 02/12/21 25/01/22 99 3. Pricing and Reimbursement For personal use only Market research conducted with specialists, funding authorities and patients in US, UK, DE and FR. • Representative cross section of global pricing and reimbursement scenarios. • Blinded - product and company
Slide 14: PPS via SAS and EAP
Paradigm Biopharma 02/12/21 25/01/22 1010 4. PPS via SAS and EAP For personal use only Special Access Scheme (SAS) • First revenue via the provision of Zilosul® (injectable Pentosan Polysulfate Sodium (iPPS)) under the pay-for-use SAS. • Under the TGA SAS, Zilosul® has been made available to physici
Slide 15: Commercialisation Options
Paradigm Biopharma 02/12/21 25/01/22 1111 5. Commercialisation Options For personal use only Preference is to partner • Maintain optionality to bring Zilosul to market ourselves De-risked phase 3 asset with globally accepted trial design in key markets Increased inbound interest in partnering OA sin
Slide 16: Pipeline
Paradigm Biopharma 25/01/22 12 5. Pipeline For personal use only • Developing new indications in parallel to lead program in OA Indication / Action of PPS Stage of Development Mucopolysaccharidosis (MPS) • Reduction of tissue GAGs • MPS I (AUS) :Open label trial currently enrolling up to 10 subjects
Slide 17: Improving value of the Asset
Paradigm Biopharma 02/12/21 25/01/22 1313 6. Improving value of the Asset For personal use only Clinical program will support broad label, maximise reimbursed price and market penetration from launch. Clinical and commercial activities to improve Zilosul label • 006 & 007 determine long term durabil
Slide 18: Investor Engagement and Global Focus
Paradigm Biopharma 02/12/21 25/01/22 1414 7. Investor Engagement 8. Global Focus For personal use only • Company Rebranding: In January 2021 Paradigm During the year we took several steps to continue to build successfully rebranded at the JP Morgan Healthcare our organisation to support commercialis
Slide 19: Newsflow Remainder of FY 2022
Paradigm Biopharma 02/12/21 25/01/22 1515 Newsflow Remainder of FY 2022 For personal use only ü First Ph3 AU patients dosed • UK ethics approval • First patient dosed US – 002 recruitment update • EAP retreatment approval • 008 last patient randomised (100% recruitment) • Pipeline indications – Next
Slide 20: For more information
For personal use only Paradigm Biopharma 25/01/22 16 For more information please visit: paradigmbiopharma.com or email any queries to investorrelations@paradigmbiopharma.com
Paradigm Biopharmaceuticals — Shareholder Meeting (January 2022) on 6ix